Roth Capital Reiterates Upbeat View of Cytori Therapeutics Inc Following FY14 Results
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytori Therapeutics Inc (NASDAQ:CYTX) with a $6 price target, after the company reported 2014 results, posting EPS of ($0.48) compared with Pantginis’ estimate of ($0.50). Cytori shares are currently trading at $1.07, down $0.08 or 6.96 percent.
Pantginis noted, “Following an important “re-start” of the company, we project a significant increase in visibility for the company in 2015. This remainder of the year will be spent by the company: 1) starting a pivotal program in scleroderma, 2) releasing data from different therapeutic indications and 3) moving forward with a broad based business development strategy.
Bottom line, “We continue to view Cytori as a leading regenerative medicine player and believe current valuations are attractive following a “re-boot” of the company.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of 18.2% and a 58.6% success rate. Pantginis has a 72.9% average return when recommending CYTX, and is ranked #31 out of 3511 analysts.